LONG v. ABBOTT LABORATORIES

1999 NCBC 10
CourtNorth Carolina Business Court
DecidedJuly 30, 1999
Docket97-CVS-8289
StatusPublished
Cited by3 cases

This text of 1999 NCBC 10 (LONG v. ABBOTT LABORATORIES) is published on Counsel Stack Legal Research, covering North Carolina Business Court primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
LONG v. ABBOTT LABORATORIES, 1999 NCBC 10 (N.C. Super. Ct. 1999).

Opinion

LONG v. ABBOTT LABORATORIES, 1999 NCBC 10

STATE OF NORTH CAROLINA IN THE GENERAL COURT OF JUSTICE

COUNTY OF MECKLENBURG SUPERIOR COURT DIVISION

97-CVS-8289

STACY LEE LONG, on Behalf of Himself and all Other Similarly ) ) Situated Individuals, ) ) Plaintiff, ) ) ORDER ON PETITION vs. ) FOR ATTORNEY FEES ) ABBOTT LABORATORIES; ) AMERICAN HOME PRODUCTS ) CORPORATION; BOEHRINGER ) INGELHEIM PHARMACEUTICALS, ) INC.; BRISTOL-MYERS SQUIBB ) COMPANY; BURROUGHS- ) WELLCOME CO. ; KNOLL ) PHARMACEUTICAL COMPANY; ELI ) LILLY AND COMPANY; FOREST ) LABORATORIES, INC.; GLAXO, INC.; ) HOFFMANN-LAROCHE, INC.; ) JOHNSON & JOHNSON ) PHARMACEUTICAL TRADING CO., ) INC.; MERCK & CO., INC.; MARION ) MERRELL DOW, INC.; PFIZER, INC.; ) NOVARTIS PHARMACEUTICALS ) CORPORATION; THE PERDUE ) FREDERICK COMPANY; RHONE- ) POULENC RORER ) PHARMACEUTICAL INC.; SCHERING ) CORPORATION; SCHERING- ) PLOUGH CORPORATION; G.D. ) SEARLE & CO.; SMITHKLINE ) BEECHAM PHARMACEUTICALS ) CO.; THE UPJOHN COMPANY; ) WARNER-LAMBERT COMPANY; and ) ZENECA, INC., ) ) ) ) Defendants. ) ) )

{1} This matter is before the Court on class counsel’s petition for attorney fees. For the reasons set forth below, class counsel are awarded, in the Court’s discretion, fees and expenses totaling $961,117.92.

I. A.

{2} This class action is one of eleven separate class actions filed in eleven separate jurisdictions. The actions are listed on Appendix A attached hereto and will hereinafter be referred to as the "Actions," or "Action" when referring to an individual case. The Actions were virtually identical and prosecuted on a coordinated basis. (Affidavit of Bernard Persky Applicable to Indirect Purchaser Actions, para. 1, hereinafter "Persky Affidavit.") The class representatives in each Action sought to represent the same class: consumers in each jurisdiction who purchased (indirectly from defendants) brand name drugs at retail drugstores.

{3} Each separate class action is based upon the same allegations: that the defendants violated either antitrust laws, consumer protection laws or both in each jurisdiction by selling brand name drugs to health maintenance organizations (HMOs) and mail order pharmacies at a discount to the price at which the same drugs were sold to retail pharmacies (the "two tiered pricing system"). The defenses in each jurisdiction were the same. First, defendants asserted that the class representatives lacked standing to bring the Actions since they were indirect purchasers. Second, defendants asserted that no conspiracy to fix prices existed and that their two tiered pricing system was justified by market conditions based on the differing leverage asserted in the purchasing process by their respective kinds of customers. HMOs could control what prescriptions were written, while retail pharmacists only filled the prescriptions brought to them. HMOs had leverage because of their power to control the prescription process. That leverage had expanded as HMOs and mail order pharmacies grew in size and control of the health services market. The two tiered pricing system has been in effect for many years.

{4} Since each Action sought class treatment, class certification issues existed in all cases.

{5} The Actions were not the first claims asserted against these defendants for violation of the antitrust laws arising out of the two tiered pricing system. Prior to any of the Actions being filed, retail pharmacies and other direct purchasers from the defendants filed many cases in various federal courts alleging that the two tiered pricing system violated the Sherman Anti-Trust Act. 15 U.S.C. § 1 (1994). No similar cases were brought on behalf of indirect purchasers because the federal courts do not recognize indirect purchaser standing to assert violations of federal antitrust laws. See Illinois Brick Co. v. Illinois, 431 U.S. 720, 52 L. Ed. 2d 707 (1977). Under federal case law, only the direct purchaser (the retail drug store in this case) could recover for alleged violations, and defendants could not plead that the increased costs were passed through to another level in the distribution chain. Hanover Shoe, Inc. v . United Shoe Machinery Corp., 392 U.S. 481, 20 L. Ed. 2d 1231 (1968). The federal cases were consolidated by the Judicial Panel for Multidistrict Litigation and assigned to one judge, the Honorable Charles P. Kocoras, for management (the "MDL Litigation"). See In re Brand Name Prescription Drug Antitrust Litigation , No. 94 C 897, MDL No. 997, 1994 U.S. Dist. LEXIS 16658 (N.D. Ill. Nov. 15, 1994). Part of the litigation before Judge Kocoras included a class action brought on behalf of indirect purchasers in Alabama. Judge Kocoras refused to certify the Alabama Action as a class action, citing the complications arising from tracing the "pass on" of overcharges to customers through the various levels of the chain of distribution. Id. at *19. Judge Kocoras did certify a class of retailers who were direct purchasers.

{6} Thus, at the end of 1994, a retailer class action was proceeding in federal court, and in the only state- based indirect purchaser case, the court had declined to certify a class.

B.

{7} Beginning in January 1995, class counsel filed "the first wave of coordinated indirect purchaser actions." (Persky Aff. para. 12.) In this context, "class counsel" consisted of six law firms that affiliated for the purpose of pursuing indirect purchaser cases against the defendants. (Persky Aff. para. 8.) Where necessary, the six firms then associated local counsel in each jurisdiction. Appendix C attached hereto details the law firms involved, whether they were class counsel or local counsel, and the time devoted by each to the coordinated effort in all jurisdictions. As Mr. Persky stated in his affidavit: "This coordination of effort, in practice, was intended to, and did, work in much the same manner as in federal actions coordinated by orders of the Judicial Panel on Multidistrict Litigation, with the informal appointment of ‘lead counsel’ and division of duties, responsibilities and expenses among the counsel involved." (Persky Aff. para. 1.) Unlike federal multidistrict litigation, no state court had jurisdiction to order anything done in any other jurisdiction, and, unlike federal multidistrict litigation, the process of determining lead counsel and allocation of responsibilities and expenses was by self-selection of class counsel, not by order of any court. In addition, unlike most federal multidistrict antitrust cases, the legal basis of each state action was different.

{8} Actions were filed in those jurisdictions in which indirect purchasers had been granted standing by statute or case law and those jurisdictions where it was unclear whether indirect purchasers had standing to sue for violations of state antitrust laws. Thus, Actions were initially filed in eight states and the District of Columbia. North Carolina was not in the first wave.

{9} The "second wave" consisted of Actions in Kansas (1996), Tennessee (1997) and Florida (1997). (Persky Aff. para. 40.) These Actions became mired in a procedural battle over whether they would be tried as part of the federal multidistrict litigation or as individual state cases. The cases were removed to federal court, consolidated with the multidistrict litigation, appealed to the Seventh Circuit Court of Appeals, remanded to the federal district court and subsequently back to the respective state courts. The protracted procedural battles over jurisdiction in the second wave cases had already ended when this settlement was reached.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Blitz v. Agean, Inc.
677 S.E.2d 1 (Court of Appeals of North Carolina, 2009)
In Re Wachovia S'holders Litig.
2003 NCBC 10 (North Carolina Business Court, 2003)
BRUGGERS v. EASTMAN KODAK CO.
2000 NCBC 3 (North Carolina Business Court, 2000)

Cite This Page — Counsel Stack

Bluebook (online)
1999 NCBC 10, Counsel Stack Legal Research, https://law.counselstack.com/opinion/long-v-abbott-laboratories-ncbizct-1999.